Currently, the biomarkers that have been identified for potential targeted therapy treatments for lung cancer are: EGFR, ALK, KRAS, MET, HER2, ROS1, BRAF, RET, NTRK1, PID3CA, MED1, VEGFR2, HER3, and IGF-1R. Of those, so far only EGFR, ALK+, and ROS1 have treatments approved by the FDA. However, there are many more treatments that are in clinical trials.
In this section of the Hope With Answers series, learn more about the ALK+ biomarker and the most current information available regarding approved treatments.
Hope With Answers Video Series: Biomarker ALK+
Patient and Advocate Shelly Engfer-Triebenbach speaks with lung cancer researcher Dr. Alice Shaw from Massachusetts General Hospital about ALK+ lung cancer.